Population Pharmacokinetic Modeling for Ceftazidime‐Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older

医学 肾功能 阿维巴坦 人口 头孢他啶 头孢他啶/阿维巴坦 肺炎 药代动力学 肾脏疾病 细菌性肺炎 内科学 外科 环境卫生 细菌 生物 铜绿假单胞菌 遗传学
作者
Richard C. Franzese,Todd Riccobene,Timothy J. Carrothers,Manoli Vourvahis,Erica Winter,Mark Lovern,Lynn McFadyen
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:113 (1): 182-195 被引量:2
标识
DOI:10.1002/cpt.2764
摘要

Ceftazidime‐avibactam is a novel β‐lactam/β‐lactamase inhibitor combination developed to treat serious Gram‐negative bacterial infections; approved indications include complicated urinary tract infection, complicated intra‐abdominal infection, and hospital‐acquired pneumonia including ventilator‐associated pneumonia in patients ≥ 3 months old. Because of the predominantly renal clearance of ceftazidime and avibactam, dose adjustments (reductions) are required for patients with estimated creatinine clearance (CrCL) ≤ 50 mL/min. We describe the application of combined adult and pediatric population pharmacokinetic models in developing ceftazidime‐avibactam dose recommendations for pediatric patients ≥ 2 to < 18 years old with body surface area‐normalized CrCL ≤ 50 mL/min/1.73 m 2 , including moderate, severe, or very severe renal impairment, or end‐stage renal disease requiring hemodialysis, and for patients ≥ 3 months to < 2 years old with mild, moderate, or severe renal impairment. Models included allometric scaling for all subjects and simulations (1,000 subjects per age group, renal function group, and indication) were performed nonparametrically using post hoc random effects. Doses were selected based on simulated pediatric patients achieving steady‐state exposures similar to adults and high probability of target attainment (using a simultaneous joint target for both ceftazidime and avibactam). Because there were few children with renal impairment in the ceftazidime‐avibactam clinical trials, selected pediatric doses were guided by extrapolation and matching of adult exposures associated with efficacy and within established safety margins. The recommended doses for pediatric patients with estimated CrCL ≤ 50 mL/min/1.73 m 2 use equivalent adjustments in dose quantity and/or administration interval (vs. the corresponding age group with normal renal function) as those for adults.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
包容的雁枫完成签到,获得积分10
1秒前
2秒前
yin发布了新的文献求助30
4秒前
小马甲应助ping采纳,获得10
5秒前
简单的纸飞机完成签到,获得积分10
7秒前
阿腾发布了新的文献求助10
8秒前
8秒前
11秒前
闪闪的绮菱完成签到,获得积分20
14秒前
14秒前
shen发布了新的文献求助10
14秒前
sandra发布了新的文献求助10
16秒前
xiaofeiyan发布了新的文献求助20
18秒前
18秒前
踏实啤酒完成签到,获得积分10
23秒前
24秒前
小张完成签到,获得积分10
25秒前
量子星尘发布了新的文献求助10
26秒前
27秒前
快乐的90后fjk完成签到 ,获得积分10
28秒前
现代书雪发布了新的文献求助10
29秒前
yy完成签到,获得积分10
29秒前
小屋完成签到 ,获得积分10
30秒前
31秒前
32秒前
35秒前
35秒前
渡川发布了新的文献求助10
37秒前
38秒前
吃彭彭的丁满完成签到,获得积分10
38秒前
38秒前
Akim应助YQ采纳,获得10
40秒前
shen发布了新的文献求助30
40秒前
Survivor完成签到,获得积分10
41秒前
SSS发布了新的文献求助10
41秒前
pgg发布了新的文献求助10
41秒前
辛勤迎海发布了新的文献求助10
42秒前
maitiandehe完成签到,获得积分10
42秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976418
求助须知:如何正确求助?哪些是违规求助? 3520512
关于积分的说明 11203586
捐赠科研通 3257127
什么是DOI,文献DOI怎么找? 1798594
邀请新用户注册赠送积分活动 877804
科研通“疑难数据库(出版商)”最低求助积分说明 806523